Key facts
- Maiwei Chongqing’s last known valuation is $333.1M (Dec 2024).
- It has raised $275.7M; the latest was Seed Round ($55.1M) in Dec 2024.
- Notable investors include China-Singapore Connectivity Investment Fund Management.
- Status: Privately Held (backing).
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Maiwei Chongqing
- ·The full record, as it builds
Funding rounds
No funding rounds for Maiwei Chongqing are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Maiwei Chongqing
Developer and provider of a CDMO advanced manufacturing base intended for the bone health sector. The company offers research and development, drug approvals (including production licenses), commercial manufacturing, and sales, enabling the bone health industry with innovative drug solutions.
- Sector
- Healthcare
- HQ
- Chongqing, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Maiwei Chongqing doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Maiwei Chongqing shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Maiwei Chongqing in its N-PORT filings yet. We sweep new filings monthly.